Related Experiment Videos
[Contraindications of thrombolytic therapy in acute myocardial infarct]
M Genoni1, R Malacrida, A Maggioni
1Clinica Medica Ospedale Civico, Lugano, Schweiz.
Insights
Many patients excluded from the ISIS-3 trial for myocardial infarction could have received thrombolytic therapy. Updated guidelines enable more patients to benefit from this critical treatment.
Area of Science:
- Cardiology
- Clinical Trials
- Medical Guidelines
Background:
- The ISIS-3 trial investigated treatments for myocardial infarction.
- Patient exclusion criteria for thrombolytic therapy were a significant concern.
- Understanding contraindications is crucial for effective treatment.
Purpose of the Study:
- To analyze patient exclusions from the ISIS-3 trial.
- To evaluate the impact of contraindications on thrombolytic therapy administration.
- To assess the effect of new guidelines on patient eligibility for thrombolysis.
Main Methods:
- Analysis of patient data from 43 Swiss hospitals.
- Review of exclusion reasons for patients with myocardial infarction.
- Comparison of contraindications against established and new treatment guidelines.
Main Results:
- 824 patients were included in the ISIS-3 trial; 504 were excluded.
- One-third of excluded patients lacked clear contraindications for thrombolysis.
- 27% of excluded patients had only relative contraindications.
Conclusions:
- A substantial number of patients were excluded from thrombolytic therapy due to overly strict or outdated contraindications.
- Newer guidelines for thrombolytic therapy broaden patient eligibility.
- Revised guidelines can increase the number of myocardial infarction patients benefiting from thrombolysis.
Abstract:
In 43 Swiss hospitals, 824 patients have been included in the ISIS-3 trial with suspected or proven myocardial infarction. Another 504 patients with proven myocardial infarction have been excluded for various reasons and have been registered in the study log-book (total 1328 patients). The usual clinical contraindications for thrombolysis are listed and discussed in this paper. 1/3 of those patients excluded from the trial had not received thrombolysis without clear contraindications (age, diabetes, anticoagulation, candidates for a pace-maker) and another 27% have had only relative contraindications (resuscitation, puncture, ulcer pain, hypertension). The new guidelines for thrombolytic therapy allowed more patients to benefit from this therapy.